Yuen MF - Search Results

1

Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.

Yuen MF, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, Lim YS, Cheng W, Sievert W, Visvanathan K, Ruby E, Liaw S, Yan R, Huang Q, Colonno R, Lopatin U. Yuen MF, et al. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166. doi: 10.1016/S2468-1253(19)30346-2. Epub 2019 Nov 9. Lancet Gastroenterol Hepatol. 2020. PMID: 31711752 Clinical Trial.

2

Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children.

Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Yuen MF, et al. Hepatology. 1999 Mar;29(3):924-7. doi: 10.1002/hep.510290327. Hepatology. 1999. PMID: 10051499 Clinical Trial.

3

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection.

Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, Lai CL. Wong WM, et al. Among authors: yuen mf. Hepatology. 2000 Jan;31(1):201-6. doi: 10.1002/hep.510310129. Hepatology. 2000. PMID: 10613746

4

Profound suppression of hepatitis B virus replication with lamivudine.

Lai CL, Yuen MF. Lai CL, et al. Among authors: yuen mf. J Med Virol. 2000 Jul;61(3):367-73. doi: 10.1002/1096-9071(200007)61:3<367::aid-jmv15>3.0.co;2-a. J Med Virol. 2000. PMID: 10861648 Review.

5

Natural history of chronic hepatitis B virus infection.

Yuen MF, Lai CL. Yuen MF, et al. J Gastroenterol Hepatol. 2000 May;15 Suppl:E20-4. doi: 10.1046/j.1440-1746.2000.02123.x. J Gastroenterol Hepatol. 2000. PMID: 10921377

6

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.

Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Yuen MF, et al. Hepatology. 2001 Jul;34(1):139-45. doi: 10.1053/jhep.2001.25273. Hepatology. 2001. PMID: 11431745

7

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Yuen MF, et al. Hepatology. 2001 Oct;34(4 Pt 1):785-91. doi: 10.1053/jhep.2001.27563. Hepatology. 2001. PMID: 11584376 Clinical Trial.

8

Treatment of chronic hepatitis B.

Yuen MF, Lai CL. Yuen MF, et al. Lancet Infect Dis. 2001 Nov;1(4):232-41. doi: 10.1016/S1473-3099(01)00118-9. Lancet Infect Dis. 2001. PMID: 11871510 Review.

9

Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy.

Lai CL, Yuen MF, Hui CK, Garrido-Lestache S, Cheng CT, Lai YP. Lai CL, et al. Among authors: yuen mf. J Med Virol. 2002 Jul;67(3):334-8. doi: 10.1002/jmv.10075. J Med Virol. 2002. PMID: 12116023 Clinical Trial.

10

Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus.

Yuen MF, Sablon E, Yuan HJ, Hui CK, Wong DK, Doutreloigne J, Wong BC, Chan AO, Lai CL. Yuen MF, et al. J Infect Dis. 2002 Nov 1;186(9):1335-8. doi: 10.1086/344327. Epub 2002 Oct 11. J Infect Dis. 2002. PMID: 12402204

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

585 results

Search Page